What factors drove the changes in Integer Holdings's revenue and profit?

What does Integer Holdings do and what are its main business segments?

Did Integer Holdings beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Integer Holdings next quarter?

What were the key takeaways from Integer Holdings's earnings call?

What were the key takeaways from Integer Holdings’s earnings call?

What is the revenue and EPS growth rate for Integer Holdings year over year?

What guidance did Integer Holdings's management provide for the next earnings period?

- **2025 Strong Execution**: 8% sales growth, 21% EPS increase, and $105M free cash flow.
- **2026 Outlook**: Flat to +3% organic sales, -2% to +6% EPS, with 3 new product headwinds.
- **Long-Term Growth**: 200+ basis points above-market growth in 2027, supported by 15-20% pipeline CAGR.
- **Share Buyback**: $50M ASR to enhance shareholder returns.

**【CEO Summary Section】**
- **2025 Financial Highlights**: Reported sales of $1.854 billion (+8% YoY), adjusted EPS of $6.0 (+21%), and free cash flow of $105 million.
- **2026 Outlook**: Flat to +3% organic sales growth, adjusted EPS of $6.29-$6.78 (-2% to +6%), and $50M accelerated share repurchase program.
- **Strategic Focus**: Maintaining 2.5-3.5x net debt leverage, disciplined capital allocation, and returning to 200+ basis points above-market growth in 2027.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: $472M sales (+5% reported, +2% organic), $106M adjusted EBITDA (+11%), and $1.76 adjusted EPS (+23%).
- **2026 Guidance**: $1.826-$1.876B sales (-1% to +1%), $391-$415M adjusted EBITDA (-3% to +3%), and $216-$232M adjusted net income (-4% to +3%).
- **Headwinds**: 3 new products expected to reduce sales by 3-4%, partially offset by 4-6% growth in underlying business.

**【Q&A Highlights】**
- **Sales Narrowing**: Organic range tightened to flat to +3% due to 3 new product headwinds, but core business expected to grow in line with market.
- **Margin Management**: Q1 operating margin expected to decline 200-250bps due to fixed cost absorption, improving sequentially.
- **Pipeline Confidence**: 40+ PMA-stage customers with 15-20% CAGR potential, supporting 2027 growth目标.
- **Share Repurchase**: $50M ASR program to reduce shares by ~1%, enhancing EPS.

Integer Holdings Corporation (ITGR) Q4 2025 Earnings Call Transcript

- **Q3 2025 Strong Performance**: 8% sales growth, 14% operating income growth, $1.79 EPS (25% YoY increase).
- **2025 Outlook Adjustment**: $16M sales reduction due to 3 underperforming products, revised to 7-8% sales growth.
- **2026 Challenges**: Flat to +4% organic sales growth, 5-6% EPS decline risk, 3-4% headwind from 3 products.
- **Long-Term Growth**: 2027+ above-market growth driven by 39 emerging customers and 10 launching PMA products.
- **Margin Resilience**: 17.4% operating margin target maintained, cost control and IPS efficiency to offset volume decline.

**【CEO Summary Section】**
- **Joe Dziedzic's Farewell Remarks**: Reflected on 8 years of leadership, noting 39% sales growth (2022-2025), 77% adjusted operating income growth, and 73% adjusted EPS growth. Highlighted transition to Payman Khales as CEO, emphasizing confidence in long-term strategy despite short-term headwinds.
- **Payman Khales' Inaugural Remarks**: Acknowledged strong Q3 results (8% reported/7% organic sales growth, 14% adjusted operating income growth) but announced $16M sales reduction for 2025 due to slower-than-expected adoption of 3 new products (2 EP, 1 neuromodulation). 2025 outlook revised to 7-8% sales growth, 12-14% adjusted operating income growth, and 19-21% adjusted EPS growth.
- **2026 Outlook**: Organic sales expected to be flat to +4% (reported -2% to +2%), with headwinds from 3 underperforming products (3-4% drag) offset by 4-7% growth elsewhere. Adjusted operating income and EPS expected to decline 5-6% or grow 4-5%. 2027 outlook remains +200bps above market growth driven by pipeline.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: 
  - Sales: $468M (+8% reported, +7% organic)
  - Adjusted EBITDA: $106M (+11% YoY)
  - Adjusted Operating Income: $106M (+14% YoY)
  - Adjusted EPS: $1.79 (+25% YoY)
- **2025 Full Year Guidance**: 
  - Sales: $1.84-1.85B (7-8% growth)
  - Adjusted Operating Income: $319-325M (12-14% growth)
  - Adjusted EPS: $6.29-6.43 (19-21% growth)
- **Cash Flow**: Free cash flow expected to grow 35% YoY to $130-140M.
- **Tax Rate**: Full year adjusted effective tax rate improved to 17-18% (vs. prior 18.5%).

**【Q&A Highlights】**
- **EP Product Headwinds**: 2 electrophysiology products with Q3 2025 ramp saw slower-than-expected adoption, causing 2026 sales decline. Customers revised forecasts due to market demand underperformance.
- **Neuromodulation Impact**: 1 emerging customer's PMA product adoption slower than expected, contributing to CRM&amp;N sales decline.
- **Pipeline Confidence**: 39 emerging customers with PMA products, 10 in launch phase, driving long-term growth despite short-term volatility.
- **Cost Management**: Disciplined expense control and Integer Production System (IPS) efficiency to mitigate margin pressure.
- **Backlog Visibility**: $730M backlog (1.5+ quarters visibility) remains stable, despite near-term product underperformance.


Integer Holdings Corporation (ITGR) Q3 2025 Earnings Call Transcript

- **Q2 Growth Surpasses Expectations**: 11% revenue growth, 15% operating income expansion, and 19% EPS increase highlight strong execution.
- **Full Year Outlook Raised**: Midpoint targets of 8.5% sales growth, 14% operating income growth, and 20% EPS growth reflect confidence in margin expansion and new product pipelines.
- **C&V Dominance**: 24% Q2 growth and 17% trailing 4Q growth underscore leadership in electrophysiology and neurovascular markets.
- **CRM&N Turnaround**: Mid-single-digit full-year growth driven by neuromodulation recovery and declining legacy program impact.
- **Financial Strength**: 3.2x leverage ratio, 19% tax rate, and 55% free cash flow improvement demonstrate disciplined capital allocation.

**【CEO Summary Section】**
- Q2 2025 revenue grew 11% YoY to $476 million, driven by strong demand across all product lines. Adjusted operating income increased 15% to $99 million, and EPS rose 19% to $1.55.
- Full year 2025 outlook updated: sales growth of 8.5% (midpoint), adjusted operating income up 14%, and EPS up 20% (midpoint). Guidance tightening reflects high visibility to second-half demand.
- Cardio & Vascular (C&V) sales surged 24% Q2, with trailing 4Q growth of 17%, driven by new product ramps and acquisitions. CRM & Neuromodulation (CRM&N) grew 2% Q2, with full-year guidance raised to mid-single digits.
- Emphasized margin expansion through manufacturing efficiency and tuck-in acquisitions, with net debt leverage at 3.2x (within 2.5x-3.5x target range).

**【CFO Financial Commentary】**
- Adjusted EBITDA of $99 million (+10% YoY) and adjusted net income of $55 million (+23% YoY) highlighted operational improvements and tax rate reduction to 19%.
- Free cash flow improved 55% YoY to $25 million, with full-year cash flow forecast at $235-255 million (+20% YoY midpoint).
- FX headwind of $0.09 EPS in Q2, with hedging program expanded to mitigate future volatility.
- 2025 outlook includes $1.863 billion sales midpoint, 11%-16% EBITDA growth, and 18%-23% EPS growth, supported by 60-80 basis points margin expansion.

**【Q&A Key Highlights】**
- **Organic Growth**: Q2 outperformance ($10M vs. high-single-digit guidance) due to demand pull-forward, new product ramps, and manufacturing efficiency. Second-half growth expected at 8% (vs. 9% first-half), with C&V mid-teens and CRM&N mid-single digits.
- **CRM&N Recovery**: Second-half growth to 8-9% (vs. 2% H1) driven by neuromodulation demand and declining impact of a legacy program.
- **Tariff Impact**: Minimal ($1-5M annual), with ongoing efforts to reduce to near-zero.
- **Contract Flexibility**: 70% of business under multiyear contracts with 12-month visibility, enabling efficient manufacturing planning.
- **Backlog Stability**: $700M backlog (similar to Q1) provides confidence in second-half execution despite tough 4Q 2024 comp.


Integer Holdings Corporation (ITGR) Q2 2025 Earnings Call Transcript

- **CEO Transition**: Joe Dziedzic retiring in October 2025, with Payman Khales succeeding after 7+ years of C&V leadership success.
- **Q1 2025 Results**: 7% revenue growth, 14% EBITDA expansion, EPS up 15% YoY. Full year EPS outlook raised to +16%-23% YoY.
- **Strategic Momentum**: C&V mid-teens growth, CRM&N low-mid single digits. $1B debt refinancing reduces interest expense by $13M.
- **Tariff Resilience**: Minimal impact ($1M-$5M) due to U.S. supplier base; 2026 outlook unchanged.
- **Margin Expansion**: Operating margin to expand 76bps YoY, driven by manufacturing efficiency and acquisitions.


**【CEO & CEO-Elect Transition】**
- CEO Joe Dziedzic announced his planned retirement effective October 24, 2025, with Payman Khales succeeding as CEO-Elect. Transition includes Joe staying as advisor until March 2026.
- Khales has 7+ years leading C&V business, doubling sales and improving profitability, with expanded COO responsibilities.

**【Q1 2025 Financial Highlights】**
- **Revenue**: $437M (+7% YoY reported, +6% organic). C&V up 17%, CRM&N up 2%.
- **Profitability**: Adjusted EBITDA $92M (+14% YoY). Gross margin 28.7%, up 60bps YoY.
- **EPS**: $1.31 (+15% YoY). Full year EPS outlook raised to $6.15-$6.31 (+16%-23% YoY).

**【2025 Outlook】**
- **Sales**: $1.846B-$1.880B (+8%-10% reported, +6%-8% organic). C&V expected mid-teens growth, CRM&N low-mid single digits.
- **Margin Expansion**: Operating margin to expand 76bps YoY, driven by manufacturing efficiency and sales growth.
- **Tariff Impact**: $1M-$5M estimated impact, with efforts to minimize costs.

**【Strategic Initiatives】**
- Completed 2 tuck-in acquisitions (Precision Coating, VSi Parylene) to add coating capabilities.
- Refinanced $1B convertible notes at 1.78% coupon, reducing interest expense by $13M in 2025.
- Maintaining net leverage within 2.5x-3.5x EBITDA range.

**【Q&A Key Takeaways】**
- **Tariffs**: Minimal impact ($1M-$5M) due to U.S.-based suppliers; 2026 outlook similar to 2025.
- **Order Book**: $800M backlog, expected to decline as customers reduce forward booking requirements.
- **Market Trends**: C&V growth driven by EP and structural heart; CRM&N mix shift to neuromodulation boosting growth.
- **FX & AR**: Stable collections; FX hedging mitigates volatility.


Integer Holdings Corporation (ITGR) Q1 2025 Earnings Call Transcript

- **Strong 2024 Execution**: 10% sales growth, 20% operating income expansion, and $184M net income reflect strategic execution.
- **2025 Growth Ambition**: 8-10% sales growth (6-8% organic) and 11-16% operating income growth driven by high-growth medical device markets.
- **Acquisition Impact**: $180M in tuck-in deals expand coating capabilities, targeting 15-20% CAGR in emerging PMA products.
- **Financial Discipline**: 2.6x debt/EBITDA at year-end, with 2025 free cash flow projected to grow 15% YoY.

**【CEO Opening Remarks】**
- **2024 Performance Highlights**: Q4 sales grew 11% YoY (organic and reported), full-year sales up 10% with adjusted operating income up 20%. Divested Electrochem business to focus on medical devices.
- **Acquisition Strategy**: Completed Precision Coating ($152M) and VSi Parylene ($28M) acquisitions, adding coating capabilities. 2025 outlook includes $59M inorganic growth offset by $29M decline from Portable Medical exit.
- **2025 Growth Targets**: 8-10% reported sales growth (6-8% organic), 11-16% adjusted operating income growth. Focus on high-growth markets like electrophysiology, structural heart, and neuromodulation.

**【CFO Financial Review】**
- **Q4 2024 Results**: $449M sales, $95M adjusted EBITDA (+11% YoY), $51M adjusted net income. Full-year 2024: $1.717B sales, $361M adjusted EBITDA (+19%), $184M adjusted net income.
- **2025 Outlook**: $1.846B-$1.880B sales, $401M-$422M adjusted EBITDA, $5.84-$6.20 EPS. Free cash flow expected to grow 15% YoY to $225M-$245M.
- **Leverage Management**: Ended Q4 2024 with 2.6x debt/EBITDA, targeting 2.5-3.5x range. 2025 net debt expected to rise $75M-$95M due to acquisitions.

**【Q&A Key Themes】**
- **C&V Growth**: Q4 trailing 4Q sales up 14% YoY, guided to low double-digit 2025 growth driven by EP and structural heart. CRM&N expected to grow 8% YoY with neuromodulation outperformance.
- **Tariff Mitigation**: Operating under assumption of potential U.S.-Mexico tariffs, implementing supply chain adjustments. Tariff impact unclear due to uncertain regulatory environment.
- **Acquisition Synergies**: Precision Coating and VSi Parylene expected to contribute $52M and $7M in 2025 sales. Acquisitions expand coating capabilities for high-growth medical device applications.


Actual											1.25	0.32	0.5	0.71	0.97	1.07	1.05	0.99	0.78	1.04	0.95	1.11	0.87	1.14	1.27	1.39	1.14	1.3	1.43	1.43	1.31	1.55	1.79	1.76
Forecast											0.855	0.21	0.2667	0.51	0.7267	0.8133	0.8367	0.86	0.8467	1.14	0.74	1.06	0.8325	1.0007	1.0987	1.3328	1.113	1.2281	1.3615	1.4588	1.234	1.5489	1.6876	1.6985
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+46.20%	+52.38%	+87.48%	+39.22%	+33.48%	+31.56%	+25.49%	+15.12%	-7.88%	-8.77%	+28.38%	+4.72%	+4.50%	+13.92%	+15.59%	+4.29%	+2.43%	+5.85%	+5.03%	-1.97%	+6.16%	+0.07%	+6.07%	+3.62%

ITGR

ITGR fundamentals

ITGR Q4 2025 Earnings

Earnings Call

You can ask Aime

ITGR

ITGR fundamentals

ITGR Q4 2025 Earnings

Earnings Call

ITGR Earnings Call Summary for Q4/20259:00 AM on Feb 19, 2026

ITGR Earnings Call Summary for Q3/20259:00 AM on Oct 23, 2025

ITGR Earnings Call Summary for Q2/20259:00 AM on Jul 24, 2025

ITGR Earnings Call Summary for Q1/20259:00 AM on Apr 24, 2025

ITGR Earnings Call Summary for Q4/20249:00 AM on Feb 20, 2025

You can ask Aime